# Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

> **NCT01610414** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1877 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Herpes Zoster vaccine GSK1437173A
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01610414
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-13
- **Primary completion:** 2016-11-04
- **Final completion:** 2017-02-01
- **Target enrollment:** 1877 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01610414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01610414, "Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01610414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*